Morningstar Just Grew Revenue 9.6% and Nobody's Talking About It — Here's Why That's Fine By Us

# Morningstar Just Grew Revenue 9.6% and Nobody's Talking About It — Here's Why That's Fine By Us

Morningstar is the financial world's quiet overachiever, and it just kept overachieving quietly. On July 29, the Chicago-based data-and-ratings shop posted second-quarter revenue of $663.2 million, up 9.6% year-over-year — a number that, in a market obsessed with AI darlings and meme-stock theatrics, barely made a ripple. That's on brand for MORN. This is a company that compounds in the background while everyone else is watching something shinier.

The Setup: A Rally That Ran Hot Into the Print

Let's rewind a bit, because the technical picture heading into earnings tells its own story. In the month before the July 29 print, the stock ripped roughly 25% off its lows, dragging RSI up near 70 — the kind of momentum that makes technicians nervous even when the fundamentals cooperate. Both the 20-day and 50-day moving averages were pointed firmly higher. And yet, despite that sprint, MORN was still sitting more than 30% below its 52-week high. That's the tension that's defined this stock all year: a genuinely high-quality business trading like it's still working off a hangover, even as it rallies.

The July 28 rebrand of CRSP to "Morningstar Market Indexes" — a day before earnings, no less — quietly reinforced the index-licensing moat that doesn't get enough credit in the bull case. Index licensing is sticky, recurring, and scales beautifully. It's the kind of unglamorous revenue stream that analysts underweight until it's 15% of the business and nobody can dislodge it.

Why the Bulls Have a Real Case

Strip out the noise and the numbers are legitimately good: ROE north of 30%, gross margins near 62%, and free cash flow of roughly $453 million on a trailing basis. That's not a story stock — that's a cash machine with a moat. Management has been explicit that AI is being used to scale operations, not just as a slide in the investor deck, and the CRSP rebrand plus emerging traction in products like the CPTL Capital Allocation Leaders Index suggest the growth roadmap isn't just recycled buzzwords.

At a market cap of roughly $7.97 billion as of late August, and trading around 19.8x trailing earnings, this isn't a stock priced for perfection — but it's also not priced for a discount. That's the crux of the debate.

Why We're Not Chasing It Here

Two things keep this column at "hold" rather than "backing up the truck." First, there's an $865 million debt build sitting against a contracting equity base that management hasn't fully explained — and "trust me" isn't a balance sheet item. Until that's clarified, it's a legitimate overhang, not just bear-case noise. Second, Q1 free cash flow came in soft at $53.6 million, which needs context before anyone declares the FCF story bulletproof.

Then there's the Joe Mansueto sale — 5,659 shares on August 24. On its own, it's a rounding error for a founder with his stake size, and we're not going to pretend it's a smoking gun. But insider selling always deserves a raised eyebrow, especially when it lands right after a strong quarter and a hot rally. Context matters, and the context here is "modest," not "alarming."

The Real Risk Nobody Prices In

The structural risk worth actually losing sleep over isn't the debt or the insider sale — it's disintermediation. Bloomberg and FactSet aren't going anywhere, and AI is lowering the barrier to entry for financial data tools across the board. Morningstar's moat is real, but moats erode slower than people expect right up until they don't.

The Verdict

This is a high-quality compounder trading in a reasonable-not-cheap zone, with a credible base case around $190, a bear case near $158 if the debt story turns ugly or growth stalls, and a bull case near $212 if index licensing and AI scaling deliver as advertised. That's a real range, not a coin flip. Our take: hold what you own, don't be a hero chasing the rally, and watch for management to actually explain that debt build. Morningstar doesn't need a hype cycle — it needs a balance sheet footnote. Give us that, and the rerating case gets a lot easier to write.